Adult trials
- SCANALL: Study of Nordic CML and ALL Patients using Next Generation Sequencing Analysis for Low Level Mutations
- EWALL-PH-03: An open label, 3-arm, randomised phase II study to compare the safety and efficacy of ponatinib in combination with either chemotherapy or blinatumomab with imatinib plus chemotherapy as front-line therapy for patients aged 55 years and over with Philadelphia chromosome-positive (Ph+ or BCR-ABL+) acute lymphoblastic leukemia (ALL)
- ALLTogether: A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)
- BEXMAB: A phase l/ll open-label study to assess safety, tolerability and preliminary efficacy of the clever-1 antibody bexmarilimab in combination with azacitidine or azacitidine/venetoclax in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia or acute myeloid leukemia
- LOXO-IDH-20001
- CVOB560A12101: A phase 1b, multicenter study of VOB560 in combination with MIK665 in patients with relapsed/refractory non-hodgkin lymphoma, relapsed/refractory acute myeloid leukemia, or relapsed /refractory multiple myeloma
- CHDM201H12101C: A phase Ib, multi-arm, open-label, study of HDM201 in combination with MBG453 or venetoclax in adult subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
- HO150, AMLSG 29-18: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy
- HO156, AMLSG 28-18: A phase 3, multicenter, open-label, randomized study with gilteritinib or midostaurine in combination with induction and consolidation chemotherapy followed by 1 year of maintenance treatment in patients with newly diagnosed acute myeloid leukaemia (AML) or myelodysplastic syndromes with excess blasts (MDS-EB2) with FLT3 mutations who are eligible for intensive chemotherapy
- GO42784: A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer
- Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Women with Breast Cancer Taking an Aromatase Inhibitor
- ZEST: A randomized phase 3 double-blinded study comparing the efficacy and safety of niraparib to placebo in participants with either triple-negative breast cancer or her2-negative brca-mutated breast cancer with molecular disease based on presence of circulating tumor dna after definitive therapy
- DESTINY: An open-label, multinational, multicenter, phase 3b/4 study of trastuzumab deruxtecan in patients with or without baseline brain metastasis with previously treated advanced/metastatic her2-positive breast cancer (DESTINY-Breast12)
- MO42319 KATE3: A randomized, multicenter, double-blind, placebo-controlled phase III study of the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or placebo in patients with HER2-positive and PD-L1- positive locally advanced or metastatic breast cancer who have received prior trastuzumab- (+/- pertuzumab) and taxane-based therapy (kate3)
- CA209-7FL: A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Stage II-III Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer
- IMPASSION: A phase III, randomized, double-blind, placebo-controlled, multicentre study of the efficacy and safety of atezolizumab plus chemotherapy for patients with early relapsing recurrent (inoperable locally advanced or metastatic) triple-negative breast cancer
- CLL17: A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)
- CJBH492A12101: A phase I/Ib open-label, multi-center dose escalation study of JBH492 in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Non-Hodgkin´s Lymphoma (NHL)
- MK9482-022: A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post-Nephrectomy
- MK6482-012: An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as Firstline Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (cRCC)
- MK6482-011: An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti PD-1/L1 Therapy
- INCMOR 0208-301: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
- ALTAMIRA: Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma
- XHUTCHISON 2018-689-00US1: A phase 1, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hmpl-689 in patients with relapsed or refractory lymphoma
- HMPL-523: A phase I, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hmpl-523 in patients with relapsed or refractory lymphoma
- GCT3013-05: A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
- GCT3013-02: A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma
- GCT3013-01: A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma (GCT3013-01)
- NP30179: A Multicenter, open-label, phase I study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of RO7082859 as a single agent and in combination with obinutuzumab administered after a fixed, single dose pre-treatment of obinutuzumab ( Gazyva/ Gazyvaro ) in patient with relapsed / refractory B-cell Non Hodgin`s Lymphoma
- CJBH492A12101: A phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL)
- POLAR BEAR: R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, >80 years, or fail >75 years - an open label randomized Nordic Lymphoma group. Phase III trial- NLG-LBC7
- CA224098: A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma
- EORTC 1612-MG: Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresectable or metastatic melanoma with BRAF V600 mutation: an EORTC randomized phase II study (EBIN)
- CA022-001: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
- CA030-001: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
- INCB 50465-313: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants with Myelofibrosis
- INCB 50465-304: A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
- INCB 57643-103: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants with Myelofibrosis
- MagnetisMM-5: An open-label, 3-arm, multicenter, randomized Phase 3 study to evaluate the efficacy and safety of elranatamab (PF-06863135) monotherapy and elranatamab + daratumumab versus daratumumab + pomalidomide + dexamethasone in participants with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor
- CARTITUDE-5: A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- COBRA: A randomized, open-label phase 3 study of carfilzomib, lenalidomide, and dexamethasone versus bortezomib, lenalidomide and dexamethasone (krd vs. Vrd) in patients with newly diagnosed multiple myeloma
- CC-92480-MM-001: A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma
- TALAPRO-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- TALAPRO-3: A Phase 3, Randomized, double-blind, Study of Talazoparib with Enzalutamide versus Placebo with Enzalutamide in men with DDR Gene mutated metastatic Castration-Sensitive Prostate Cancer
- ESTO-2: Impact of Atorvastatin on Prostate Cancer Progression During ADT
- SPCG17: Prostate Cancer Active Surveillance Trigger Trial (PCASTT)
- BAYER20511: Open-label, Non-randomized Phase 1, Multicenter Study to Assess Radium- 223 Biodistribution in Participants With Bone Metastatic Castration Resistant Prostate Cancer (CRPC) Receiving Radium-223 Dichloride Treatment
- CYPIDES: Safety and pharmacokinetics of ODM-208 in patients with metastatic castration-resistant prostate cancer
- ProScreen: A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer
- PRIAS: Prostate cancer Research International: Active Surveillance - guideline and study for the expectant management of localized prostate cancer with curative intent
- SPCG-15: Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial
- RAMPP: Multicentric, Prospective, Randomized Controlled Trial Comparing Best Systemic Therapy (BST) With Radical Prostatectomy or BST Alone in the Management of Men With Pauci-metastatic Prostate Cancer
- INCB 099318-122: A phase 1 study exploring the safety, tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in participants with select advanced solid tumors
- FINPROVE: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile
- TILT: A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients with Injectable Solid Tumors
- MATINS: A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients
Pediatric trials
- GEPARD: Genomics-based tools for personalized treatment to reduce chemotherapy burden in pediatric cancer (GEPARD)
- PAVO: CAR-T Long Term Follow Up (LTFU) Study (PAVO)
- ALLTogether: A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)
- LELU-study: Skeletal complications in childhood leukemia - tissue-level mechanisms
- CASSIOPEIA: A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
- EsPhALL2017/COGAALL1631: International phase III trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
- Retrospective study on osteonecrosis and venous thromboembolism in children and adolescents with Hodgkin lymphoma in Sweden, Denmark and Finland 2005-2019; incidence, treatment and late outcome.
- BIANCA: A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma NHL
- LBL 2018: International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma (LBL 2018)
- B-NHL 2013 2.2: Treatment protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (B-NHL 2013)
HUS Helsinki University Central Hospital, Comprehensive Cancer Center: haluantutkimuspotilaaksi@hus.fi
HUS Helsinki University Hospital, New Chidren’s Hospital: Clinical Trial Unit (CTU) of the new Children´s Hospital
Participation in medical research
In accordance with Finnish treatment practice, we need a referral from the attending physician to participate in the study. We also get the necessary information about the suitability for the study from the attending physician.
